Molecular testing from our Pittsburgh laboratory helps physicians judge cancer risk before deciding on surgery.
Between 20 and 30% of thyroid biopsies come back indeterminate. We give physicians and their patients the molecular detail they need to choose between surgery and monitoring.
One fine-needle aspiration sample. Two complementary views of the same nodule.
Next-generation sequencing of DNA and RNA oncogenes and mRNA fusions.
A classifier of 11 microRNAs that refines risk when mutations are weak or absent.
Actionable results that help you decide between surgery and surveillance.
Ordering and support
Testing from archival cytology slides when another platform finds the sample insufficient.
Specimen requirements
What your test means, how billing works, and who to call with a question.
Patient supportOur team processes every sample in-house. Laboratory automation went into production in 2026, and turnaround time improved 17% year over year.
Our client services team is ready to help at 800-495-9885.